FibroBiologics (Nasdaq: FBLG) presented research findings at the Society for Investigative Dermatology Annual Meeting in San Diego. Dr. Chuo Fang delivered a poster presentation titled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy" on May 9, 2025. The research showcased the potential of human dermal fibroblast (HDF) spheroids to reduce psoriasis severity in preclinical models. Chief Scientific Officer Dr. Hamid Khoja highlighted that their fibroblast-based candidate could offer a durable therapeutic option with unique immunomodulatory mechanisms, potentially providing sustained remission, reduced relapse, and fewer adverse side effects. FibroBiologics, a clinical-stage biotech company, holds 240+ patents/pending patents across various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.
FibroBiologics (Nasdaq: FBLG) ha presentato i risultati della sua ricerca al Congresso Annuale della Society for Investigative Dermatology a San Diego. Il Dr. Chuo Fang ha tenuto una presentazione poster intitolata "Potenziale immunomodulatore degli sfere di fibroblasti dermici umani nella terapia della psoriasi" il 9 maggio 2025. Lo studio ha evidenziato la capacità degli sfere di fibroblasti dermici umani (HDF) di ridurre la gravità della psoriasi in modelli preclinici. Il Chief Scientific Officer, Dr. Hamid Khoja, ha sottolineato che il loro candidato a base di fibroblasti potrebbe offrire un'opzione terapeutica duratura con meccanismi immunomodulatori unici, garantendo potenzialmente una remissione prolungata, una riduzione delle recidive e meno effetti collaterali. FibroBiologics, azienda biotecnologica in fase clinica, detiene oltre 240 brevetti e domande di brevetto in diversi ambiti clinici tra cui la guarigione delle ferite, la sclerosi multipla, la degenerazione del disco, la psoriasi, l'ortopedia, la longevità umana e il cancro.
FibroBiologics (Nasdaq: FBLG) presentó los resultados de su investigación en la Reunión Anual de la Society for Investigative Dermatology en San Diego. El Dr. Chuo Fang realizó una presentación en formato póster titulada "Potencial inmunomodulador de los esfenoides de fibroblastos dérmicos humanos en la terapia de la psoriasis" el 9 de mayo de 2025. La investigación demostró que los esfenoides de fibroblastos dérmicos humanos (HDF) pueden reducir la gravedad de la psoriasis en modelos preclínicos. El Director Científico, Dr. Hamid Khoja, destacó que su candidato basado en fibroblastos podría ofrecer una opción terapéutica duradera con mecanismos inmunomoduladores únicos, proporcionando potencialmente una remisión sostenida, menos recaídas y menos efectos secundarios adversos. FibroBiologics, una empresa biotecnológica en etapa clínica, posee más de 240 patentes y solicitudes de patente en diversas áreas clínicas, incluyendo la cicatrización de heridas, esclerosis múltiple, degeneración discal, psoriasis, ortopedia, longevidad humana y cáncer.
FibroBiologics(나스닥: FBLG)는 샌디에이고에서 열린 Society for Investigative Dermatology 연례회의에서 연구 결과를 발표했습니다. Chuo Fang 박사는 2025년 5월 9일 "건선 치료에서 인간 진피 섬유아세포 스페로이드의 면역조절 잠재력"이라는 제목의 포스터 발표를 진행했습니다. 연구는 인간 진피 섬유아세포(HDF) 스페로이드가 전임상 모델에서 건선의 중증도를 감소시킬 수 있는 가능성을 보여주었습니다. 최고 과학 책임자인 Hamid Khoja 박사는 이들의 섬유아세포 기반 후보 물질이 독특한 면역조절 메커니즘을 통해 지속적인 관해, 재발 감소 및 부작용 감소를 제공할 수 있는 내구성 있는 치료 옵션이 될 수 있다고 강조했습니다. 임상 단계의 생명공학 회사인 FibroBiologics는 상처 치유, 다발성 경화증, 디스크 변성, 건선, 정형외과, 인간 수명 연장 및 암 등 다양한 임상 분야에서 240개 이상의 특허 및 출원 중인 특허를 보유하고 있습니다.
FibroBiologics (Nasdaq : FBLG) a présenté ses résultats de recherche lors de la réunion annuelle de la Society for Investigative Dermatology à San Diego. Le Dr Chuo Fang a réalisé une présentation par affiche intitulée « Potentiel immunomodulateur des sphéroïdes de fibroblastes dermiques humains dans la thérapie du psoriasis » le 9 mai 2025. Cette recherche a mis en évidence la capacité des sphéroïdes de fibroblastes dermiques humains (HDF) à réduire la gravité du psoriasis dans des modèles précliniques. Le directeur scientifique, Dr Hamid Khoja, a souligné que leur candidat à base de fibroblastes pourrait offrir une option thérapeutique durable avec des mécanismes immunomodulateurs uniques, permettant potentiellement une rémission prolongée, une réduction des rechutes et moins d'effets secondaires indésirables. FibroBiologics, une société biotechnologique en phase clinique, détient plus de 240 brevets et demandes de brevets couvrant divers domaines cliniques, notamment la cicatrisation des plaies, la sclérose en plaques, la dégénérescence discale, le psoriasis, l'orthopédie, la longévité humaine et le cancer.
FibroBiologics (Nasdaq: FBLG) präsentierte Forschungsergebnisse auf der Jahrestagung der Society for Investigative Dermatology in San Diego. Dr. Chuo Fang hielt am 9. Mai 2025 eine Posterpräsentation mit dem Titel „Immunmodulatorisches Potenzial von humanen dermalen Fibroblasten-Sphäroiden in der Psoriasis-Therapie“. Die Forschung zeigte, dass humane dermale Fibroblasten (HDF)-Sphäroide die Schwere der Psoriasis in präklinischen Modellen reduzieren können. Der Chief Scientific Officer Dr. Hamid Khoja betonte, dass ihr fibroblastenbasiertes Kandidatenmittel eine dauerhafte therapeutische Option mit einzigartigen immunmodulatorischen Mechanismen bieten könnte, was potenziell zu anhaltender Remission, weniger Rückfällen und geringeren Nebenwirkungen führt. FibroBiologics, ein Biotechnologieunternehmen in der klinischen Phase, besitzt über 240 Patente und Patentanmeldungen in verschiedenen klinischen Bereichen, darunter Wundheilung, Multiple Sklerose, Bandscheibendegeneration, Psoriasis, Orthopädie, menschliche Langlebigkeit und Krebs.
Positive
None.
Negative
None.
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San Diego May 7-10, 2025. The SID Annual Meeting provides a premier forum for skin biology research and education for researchers to share transformative scientific discoveries and medical innovations that improve human health.
The poster presentation entitled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy" was presented as a part of a poster session on Friday May 9, 2025. The poster highlighted FibroBiologics’ human dermal fibroblast (HDF) spheroids potential to reduce psoriasis severity in preclinical models, and offer a scalable, cell-based therapy with durable effects. A PDF version of the poster can be viewed here.
"Presenting our work at the Society for Investigative Dermatology Annual Meeting highlights our continued commitment to advancing innovative, cell-based treatments for chronic inflammatory diseases," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "Psoriasis remains a challenging chronic disease with limited long-term treatment options, and our IND-enabling preclinical data demonstrate that our fibroblast-based candidate may potentially offer a durable, therapeutic option with a unique immunomodulatory mechanism, and enable a sustained remission, reduced relapse, and a significantly lower adverse side effects profile.”
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential and capabilities of human dermal fibroblast (HDF) spheroids fibroblasts. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business, and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
What did FibroBiologics (FBLG) present at the 2025 SID Annual Meeting?
FibroBiologics presented research on human dermal fibroblast spheroids for psoriasis therapy, demonstrating their potential to reduce psoriasis severity in preclinical models.
What are the potential benefits of FibroBiologics' psoriasis treatment?
The treatment potentially offers durable therapeutic effects, sustained remission, reduced relapse rates, and a significantly lower adverse side effects profile through a unique immunomodulatory mechanism.
How many patents does FibroBiologics (FBLG) currently hold?
FibroBiologics holds 240+ US and international patents/patents pending across various clinical pathways including psoriasis, multiple sclerosis, wound healing, and cancer.
Who presented FibroBiologics' research at the 2025 SID Annual Meeting?
Dr. Chuo Fang, Senior Research Scientist at FibroBiologics, delivered the poster presentation at the meeting.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
